Opko Health Inc Revenue Growth Rates (OPK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Opko Health Inc   (NASDAQ: OPK)
 

OPK's Revenue Growth by Quarter and Year

Opko Health Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OPK Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 163.58
1st Quarter March 124.20
FY 287.78

OPKs Annual Revenue
Opko Health Inc 's Revenue in the fiscal year 2025 $ 606.88 millions
Opko Health Inc 's Revenue in the fiscal year 2024 $ 713.14 millions
Opko Health Inc 's Revenue in the fiscal year 2023 $ 863.50 millions
Opko Health Inc 's Revenue in the fiscal year 2022 $ 1,004.20 millions
Opko Health Inc 's Revenue in the fiscal year 2021 $ 1,774.72 millions




OPK Revenue second quarter 2026 Y/Y Growth Comment
Opko Health Inc reported Revenue growth of 4.32% year on year in the second quarter 2026, to $ 163.58 millions, this is lower than Opko Health Inc 's recent average Revenue rise of 70.22%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 118 other companies have achieved higher Revenue growth. While Opko Health Inc ' s Revenue increase of 4.32% ranks overall at the positon no. 2293 in the second quarter 2026.


OPK Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -19.16 % 0.95 % -1.85 %
3rd Quarter September - -12.65 % -2.78 % -0.63 %
2nd Quarter June 4.32 % -13.93 % -31.36 % -14.35 %
1st Quarter March -17.17 % -13.67 % -26.89 % -27.84 %
FY   - -14.9 % -17.41 % -

Financial Statements
Opko Health Inc 's second quarter 2026 Revenue $ 163.58 millions OPK's Income Statement
Opko Health Inc 's second quarter 2025 Revenue $ 156.81 millions Quarterly OPK's Income Statement


OPK Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -2.12 % 5.77 % 1.85 %
3rd Quarter September - -3.28 % -4.7 % -32.71 %
2nd Quarter June 31.71 % 4.57 % 4.89 % 11.72 %
1st Quarter March -16.34 % -18.35 % -4.52 % 28.19 %
FY (Year on Year)   - -14.9 % -17.41 % -


Back to OPK Growth rate Comparisons >> Back to OPK Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #119
Healthcare Sector #330
Overall #2293

Revenue Y/Y Growth Statistics
High Average Low
981.7 % 70.22 % -53.82 %
(Jun 30 2016)   (Dec 31 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #119
Healthcare Sector #330
Overall #2293
Revenue Y/Y Growth Statistics
High Average Low
981.7 % 70.22 % -53.82 %
(Jun 30 2016)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Opko Health Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
237.11 % 9.49 % -42 %
(Sep 30 2015)  


OPK's II. Quarter Q/Q Revenue Comment
Opko Health Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 31.71%, to $ 163.58 millions, from $124.20 millions in the first quarter.
OPK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Opko Health Inc 's Revenue growth quarter on quarter, overall rank is 350.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #80
Overall #350
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #80
Overall #350
Revenue Q/Q Growth Statistics
High Average Low
237.11 % 9.49 % -42 %
(Sep 30 2015)  


OPK's II. Quarter Q/Q Revenue Comment
Opko Health Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 31.71%, to $ 163.58 millions, from $124.20 millions in the first quarter.
OPK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Opko Health Inc 's Revenue growth quarter on quarter, overall rank is 350.


Opko Health Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 587.90 $ 581.12 $ 606.88 $ 642.07 $ 664.03
Y / Y Revenue Growth (TTM) -11.47 % -15.71 % -14.9 % -9.75 % -7.31 %
Year on Year Revenue Growth Overall Ranking # 3086 # 3076 # 2907 # 3020 # 1158
Seqeuential Revenue Change (TTM) 1.17 % -4.24 % -5.48 % -3.31 % -3.68 %
Seq. Revenue Growth (TTM) Overall Ranking # 2905 # 2705 # 2114 # 2866 # 2551


Cumulative Revenue growth Comment
Opko Health Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Opko Health Inc 's annual Revenue decline would be -11.47% year on year to $588 millions.

In the Healthcare sector 420 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3076 to 3086.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 130
Healthcare Sector # 421
Overall # 3086

Revenue TTM Y/Y Growth Statistics
High Average Low
805.93 %
 58.37 %
-43.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 130
Sector # 410
S&P 500 # 2905
Cumulative Revenue growth Comment
Opko Health Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Opko Health Inc 's annual Revenue drop would be -11.47% year on year to $588 millions.

In the Healthcare sector 420 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3076 to 3086.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 130
Healthcare Sector # 421
Overall # 3086

Revenue TTM Y/Y Growth Statistics
High Average Low
805.93 %
58.37 %
-43.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 130
Sector # 410
S&P 500 # 2905




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OPK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Schrodinger Inc 7.54%$ 7.542 millions
Boston Scientific Corporation7.53%$ 7.528 millions
Agilon Health Inc 7.15%$ 7.151 millions
Tenet Healthcare Corp6.77%$ 6.773 millions
Henry Schein Inc 6.73%$ 6.728 millions
Collegium Pharmaceutical Inc 6.67%$ 6.668 millions
Mallinckrodt Plc6.62%$ 6.617 millions
Johnson and Johnson6.60%$ 6.600 millions
Prestige Consumer Healthcare Inc 6.57%$ 6.569 millions
Msa Safety Inc6.25%$ 6.252 millions
Pacira Biosciences inc 6.24%$ 6.240 millions
Globus Medical Inc 5.94%$ 5.940 millions
Labcorp Holdings Inc 5.78%$ 5.778 millions
Tandem Diabetes Care Inc 5.77%$ 5.768 millions
Bristol myers Squibb Company5.74%$ 5.738 millions
Haemonetics Corporation5.65%$ 5.646 millions
Progyny Inc 5.58%$ 5.584 millions
Cytek Biosciences Inc 5.57%$ 5.566 millions
Amphastar Pharmaceuticals Inc 5.44%$ 5.441 millions
Becton Dickinson And Company5.44%$ 5.438 millions
Bruker Corporation5.22%$ 5.220 millions
Davita Inc 5.17%$ 5.165 millions
Park Dental Partners Inc 5.10%$ 5.102 millions
Lumexa Imaging Holdings Inc 5.08%$ 5.076 millions
Merck and Co Inc 5.07%$ 5.068 millions
Cv Sciences Inc 4.96%$ 4.958 millions
Viatris Inc 4.88%$ 4.877 millions
Fulgent Genetics Inc 4.86%$ 4.855 millions
Zimmer Biomet Holdings Inc 4.80%$ 4.799 millions
Mettler toledo International Inc 4.48%$ 4.485 millions


About Opko Health Inc Revenue Growth Rates (OPK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Opko Health Inc (CIK 944809).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-318090
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Opko Health Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.